Edward Garon

Edward Garon contributed to the foundational KEYNOTE-001 study in lung cancer that established PD-L1 as a predictive biomarker and supported pembrolizumab approval. His research helped define the optimal PD-L1 cut-points for immunotherapy benefit in NSCLC and continues to explore novel first-line IO strategies. He leads a robust thoracic oncology clinical trials program at UCLA spanning immunotherapy combinations and targeted agents. Garon's early clinical work contributed directly to the clinical development path that yielded the first PD-1 approval in lung cancer.